medigraphic.com
ISSN 0016-3813 (Print)

2009, Number 4

<< Back Next >>

Gac Med Mex 2009; 145 (4)

VI. Multifarmacorresistencia: situación actual

Salazar-Lezama MÁ

Language: Spanish
References: 24
Page: 309-312
PDF size: 50.62 Kb.


ABSTRACT

Tuberculosis is among the leading causes of death worlwide. One third of the world population is infected with Mycobacterium tuberculosis. Drug resistance to isoniazid and rifampin, the 2 most potent first-line drugs for the treatment of TB (the definition for MDRTB), is increasing globally. MDRTB is caused by the sequential acquisition of single resistance trials. This has been a consequence de poor prescribing practice by doctors, patient non-compliance with treatment ant the endogenous mutation of M. tuberculosis. Previous treatment for TB has been identified as an important risk factor for the acquisition of drug-resistant TB. The treatment of the MDRTB is difficult and may necessitate the use of second-line drugs or resectional surgery. Therefore, the management of patients should only be undertaken by, or in very close contact with, experts in this area. The individualized treatments are expensive and they are so difficult to implement in middle-low countries, which bear the highest burden of MDRTB cases. For this reason, the 1996 WHO recommendations for the treatment of MDRTB favored the use of standardized treatments in specific circumstances. The treatment of the XDRTB always has be individualized.


REFERENCES

  1. Martínez MD, López SE, Torres CA, Ruiz PV, Mora PM, Salazar LMA. Consideraciones a los resultados de tratamiento en pacientes con tuberculosis resistente a múltiples fármacos (TBMDR). Una revisión de la literatura. Neumol Cir Torax 2008;67:34-43.

  2. Nolan CM, Williams DL, Cave MD, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995;152:1067.

  3. Wright A, Zignol M. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva, Switzerland: World Health Organization; 2008.

  4. Kritzki AL, Rodrígues de Jesús LS, Andrade MK, Werneck-Barroso E, Monteiro MA, Haffner A, Riley LW. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997;111:1162-1167.

  5. Mendoza MT, Gonzaga AJ, Roa C, Velmonte AV, Jorge M, Montoya JC, Tan Torres C, Ong M, Barez MYC, Ang CF. Nature of drug resistance and predic tors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines. Int J Tuberc Lung Dis 1997;1:59-63.

  6. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006;10:829-837.

  7. Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, et al. Feasibility and cost-effectiveness of standardized second-line drug for chronic tuberculosis patients: A national cohort study in Peru. Lancet 2002;359:1980-1989.

  8. Stop TB Partnership (2006). Global Plan to Stop TB 2006-2015. Disponible en ghttp//www.stoptb.org/globalplan/

  9. Marris E. Extreme TB strain threatens HIV victims worldwide. Nature 2006;443:131.

  10. Baleta A. Forced isolation of tuberculosis patients in South Africa. Lancet Infect Dis 2007;7:771.

  11. Iseman MD. Extensively drug-resistant Mycobacterium tuberculosis. Charles Darwin would understand. Clin Infect Dis 2007;45:1415-1416.

  12. WHO/IUATLD Antituberculosis Drug Resistant in the World. Fourth Global Report. WHO/HTM/TB/2008.394. Geneve, Switzerland: World Health Organization; 2008.

  13. Center for Disease Control. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs worldwide. MMWR 2006;March 24;54.

  14. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009;9:19-30.

  15. World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis. WHO/HTM/TB/2006,361. Geneve, Switzerland: World Health Organization; 2006.

  16. Crofton J, Chaulet, Maher D, et al. Guidelines for the management of drugresistant tuberculosis. WHO/TB/96.210. Geneve, Switzerland: World Health Organization; 1997.

  17. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. In J Tuberc Lung Dis 2004;8:361-368.

  18. Van Deun A, Hamid Salim MA, Kumar Das AP, Bastian I, Portaels F. Results of a standarized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004;8:560-567.

  19. Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, Farnia P, Javanmard P, Mansouri D, Velayati AA. Outcome of treatment of MDR-TB patients with standardized regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008;12:750-755.

  20. Martínez-Mendoza D, Torres CA, Villarreal VH, Báez SR, Salazar-Lezama MA. Resultado de retratamiento estandarizado en pacientes con tuberculosis resistente a múltiples fármacos (TB-MDR). Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”. México 2003-2005. Neumol Cir Torax 2009;68:7-16.

  21. Eker B, Ortamann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffman H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange Ch; German TBNET Group. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infec Dis 2008;14:1700-1706.

  22. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008;359:563-574.

  23. Holtz TH, Sternberg M, Kammerer, Laserson K, Riekstina V, Zarovska E, Skripconoka V, Wells CHD, Leimane V. Time to sputum culture conversion in multidrug-resistant tuberculosis: Predictors and relationship to treatment outcome. Ann Intern Med 2006;144:650-659.

  24. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrugresistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-161.




2020     |     www.medigraphic.com